Study finds great progress in leukemia, Lymphoma in decades past treating (HealthDay)
HealthDay Reporters by Amanda Gardner
healthday -Wed, Nov 24, 11: 47 h. HITTITES
WEDNESDAY, 24 November HealthDay News)--Clinicians did remarkable avances Treaty blood cancers and bone marrow and blood stem cell greffes in recent years, significantly reduced risk of complications related to the treatment and deaths, a new study shows.
Between in the early 1990s and 2007, there was a year that 41 percent in global risk died in an analysis of more than 2,500 patients treated in Fred Hutchinson Cancer Center in Seattle, a leader in the field of blood cancers and other malignancies.
Find the two Fred Hutchinson Cancer Center, who conducted the study, diminue dramatic treatment side effects an organ damage.
The study was published in November 24 New England Journal of medicine in
'' We had made progress in enormous knowledge of this very complex process and all the results, "said Senior study author Dr. George McDonald, a gastroenterologist and Hutchinson and a teacher medicine at University of Washington in Seattle. '' This is one of the largest complex procedures in medicine and we understand a lot of complications you front. "
Dr. Mitchell Smith, head of service UN Fox Chase Cancer Center in Philadelphia, is general positive trend--if not accurate number extrapolées can do to take care of other centers.
"More of what they did was generally adopted most transplant units, but you have to because they don't have to say two find a more population and medical experts, '' he said. Boston Centers little who is not a lot of procedures are not able to get the same accurate results, but the trend is clearly. "
Treatment without items like leukemia cancers, UN and du was in the ' 70s and introduction of allogénique your blood marrow transplantation.
Advance this meeting, in front of patients with blood cancers was far more limited option. High-dose chemotherapy treatment or traitements designed to kill cancer cell (which divide law that ordinary red blood cells) often damaged you destroyed the bone marrow patient, let his own produces cell to the work of transport oxygen, needed to fight infection and an end. /stop bleeding. Transplanter healthy stem cells from a donor in the patient's marrow--if all parties--well restored his cell to produce these important.
During the therapy met great success, it also there were a number of serious side effects, including infections, gloves and damage graft-par-host disease (GVHD), who was severe enough to prevent older and frailer patients to procedures.
But before 40 years have seen a great improvement in Des these factors.
Author of this study compared two patients who completely 1,418 the first allogéniques greffes in Hutchinson between 1993 and 1997 with 1,148 patient who was procedures a decade later, between 2003 and 2007.
The Patient types of leukemia and myelodysplastic UN multiple du syndrome and received périphériques-stem cell donor marrow you two names. In later period more périphériques-stem blood cell transplantations and less bone marrow transplantations were effectuée.
Global rate of death by a rechute refused to 52 percent, and in all early death rate (200 days post-procedure) without rechute put a 60 percent.
About 55 percent of the transplantations to patients in the early period of one year, compared with 70 percent of these later period.
After this there was improvement in the rate of just about every complication, even if patients treated in 2003-2007 was the Chief and sicker that people treated a decade earlier. For example, the chance to develop severe graft-par-host disease down to the 67 percent of the Decade, thanks to better drugs. There was also less disease and infection is not related to the treatment less damage to liver, kidney and lung, the analysis was found.
Author may not be sure about reasons for improvement, but Sur he plans to do with more controlled dose chemotherapy. less toxic "climatisation" to rid the body in the attacks lymphocytes. best disruption prevention and infection, bacteria and fongiques, as well as better if antifongiques (and other) medicine, even the best match donor countries and recipients.
Stem cell Use périphériques-, which grew during the frame, easier on the patient,.
Introduction of the drug Gleevec to treat sick with leukemia disease myéloïde éliminés was needed in transplantation patients, in addition, added Smith.
"I think we all feel comfortable what we are doing better than you did 10 years ago, particularly in terms of early deaths and avoidance of Des toxicity, and those who came from out of this land Group [the Fred Hutchinson Cancer Center]," Smith said. "Who will lead the way."
Dr. Nelson C., head of the program and transplantation medicine teachers in Every University in Durham, N. C., agreed that "many traitements what they are now Standard in many places."
McDonald and five other author reported ties with the company pharmaceutique. The study was set up by the U.s. National Institute of health.
More information
Leukemia & Lymphoma Society will be more about stem cell transplantation.
Comments
Post a Comment